Form 4: Tandem Diabetes Care Executive Awarded Significant Equity Compensation

Tandem Diabetes Care's EVP & Chief Administrative Officer, Susan Morrison, was granted 20,768 Performance Stock Units and 20,768 Restricted Stock Units under the company's 2023 Long-Term Incentive Plan.

Summary

• Susan Morrison, Executive Vice President and Chief Administrative Officer of Tandem Diabetes Care Inc. (TNDM), reported new equity awards on May 30, 2025.
• She was granted 20,768 Performance Stock Units (PSUs) and 20,768 Restricted Stock Units (RSUs) as part of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan.
• The PSUs are contingent rights to receive common stock, with the number of shares ranging from 0% to 200% based on pre-defined performance metrics by December 31, 2027, and continued service.
• The RSUs represent a contingent right to receive common stock or cash, with 33% vesting on May 15, 2026, and the remainder vesting in eight equal quarterly installments thereafter.
• Following these transactions, Ms. Morrison directly beneficially owns 37,206 shares of Common Stock.

Sentiment

Score: 7

Explanation: The granting of performance-based and restricted stock units to a key executive is generally viewed positively as it aligns management's interests with long-term shareholder value creation and aids in executive retention, indicating stability in executive compensation strategy.

Positives

• The granting of equity awards, particularly performance-based units, aligns executive incentives directly with the company's long-term performance and shareholder value creation.
• The 2023 Long-Term Incentive Plan demonstrates the company's structured approach to retaining and motivating key executive talent.
• Performance Stock Units (PSUs) encourage the achievement of specific strategic and financial goals, as their vesting is tied to pre-defined company performance metrics.

Risks

• The actual number of shares received from Performance Stock Units (PSUs) can range from 0% to 200% of the awarded amount, contingent on achieving pre-defined performance metrics by December 31, 2027, and the awardee's continued service.
• Vesting of Restricted Stock Units (RSUs) is also contingent on the awardee's continued service with the company.

Future Outlook

The equity awards are part of a long-term incentive plan, indicating the company's focus on future performance and the retention of key executives. The Performance Stock Units are specifically tied to performance through December 31, 2027, aligning executive efforts with multi-year strategic objectives.

Management Comments

• The awards were made "pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto."

Industry Context

Equity compensation, particularly through Performance Stock Units (PSUs) and Restricted Stock Units (RSUs), is a common and widely accepted practice in the medical device and technology sectors. This approach is used to incentivize executive performance, align management interests with shareholder returns, and ensure long-term executive retention in competitive industries.

Comparison to Industry Standards

• The use of a combination of Performance Stock Units (PSUs) and Restricted Stock Units (RSUs) for executive compensation is a standard practice across publicly traded companies, particularly in high-growth and R&D-intensive sectors like medical devices.
• The structure, which includes both performance-based vesting (PSUs) and time-based vesting (RSUs), is a typical approach to balance the achievement of long-term strategic goals with executive retention, consistent with compensation strategies observed in companies such as Medtronic, Dexcom, or Insulet, which also operate in the diabetes technology space.

Corporate Governance

Related Party Transactions

• The equity awards to Susan Morrison, an executive officer, constitute a related party transaction, which is a standard compensation event disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders: Potential positive impact through enhanced executive alignment with long-term company performance and strategic goals, which could lead to increased shareholder value.
• Employees: May signal a stable and structured approach to executive compensation, potentially influencing overall employee morale and retention strategies.

Next Steps

• Achievement of pre-defined performance metrics for Performance Stock Units (PSUs) by December 31, 2027, to determine the final number of shares to be issued.
• Vesting of Restricted Stock Units (RSUs), with the first tranche of 33% on May 15, 2026, followed by eight equal quarterly installments thereafter.

Key Dates

Keywords

Tandem Diabetes Care, TNDM, SEC Form 4, Equity Compensation, Performance Stock Units, Restricted Stock Units, Executive Compensation, Long-Term Incentive Plan, Insider Transaction